BioMarin Pharmaceutical | BMRN - Actif À Court Terme





Actif À Court Terme Changement Date
Acadia Pharmaceuticals USD 1.1B 33.9M 2026-03
Agios Pharmaceuticals USD 834.84M 107.21M 2026-03
Alnylam Pharmaceuticals USD 4.22B 168.65M 2026-03
Amgen USD 31.48B 2.42B 2026-03
Bayer EUR 35.3B 2.39B 2026-03
Biogen USD 9.19B 216.3M 2026-03
BioMarin Pharmaceutical USD 4.61B 651.58M 2026-03
Gilead Sciences USD 18.64B 1.25B 2026-03
Incyte USD 5.48B 460.36M 2026-03
Insmed USD 1.61B 181.04M 2026-03
Ionis Pharmaceuticals USD 2.94B 52M 2026-03
Moderna USD 5.77B 774M 2026-03
Neurocrine Biosciences USD 2.44B 86.6M 2026-03
PTC Therapeutics USD 2.25B 19.94M 2026-03
Puma Biotechnology USD 143.58M 7M 2025-09
Regeneron Pharmaceuticals USD 18.21B 187.3M 2026-03
Roche Holding CHF 38.73B 3.03B 2025-12
Sangamo BioSciences USD 49.89M 12.3M 2025-06
Sanofi EUR 30.95B 8.99B 2025-12
Sarepta Therapeutics USD 2.31B 228.06M 2026-03
Ultragenyx Pharmaceutical USD 657M 294M 2026-03
United Therapeutics USD 2.87B 830.5M 2026-03
Vertex Pharmaceuticals USD 11.73B 529.3M 2026-03